Patient-specific tumor-associated antigen presented on Major Histocompatibility Complex (TSA-MHC complex)

Patient-specific tumor-associated antigens (TSAs), commonly known as neoantigens, are unique peptides derived from non-synonymous somatic mutations found exclusively within a patient's tumor cells. When these antigens are processed and presented on Major Histocompatibility Complex (MHC) molecules by professional antigen-presenting cells like dendritic cells, they form a critical complex for the initiation of the adaptive immune response. This presentation is the primary signal required to prime and activate naive T cells into effector cytotoxic T lymphocytes (CTLs) capable of recognizing and destroying malignant cells. Because these neoantigens are absent from the normal human proteome, they represent ideal therapeutic targets with high specificity and a lower risk of off-target autoimmune toxicity. Therapeutic interventions, such as personalized dendritic cell vaccines or mRNA-based neoantigen vaccines, aim to enhance the presentation of these specific complexes to overcome tumor-induced immunosuppression. This personalized approach is a cornerstone of modern precision oncology, leveraging the unique genetic landscape of an individual's cancer to drive a targeted immune attack.

Other names

Neoantigen-MHC complexTumor-specific antigen (TSA)Personalized tumor-associated antigenPeptide-MHC complex (pMHC)Dendritic cell-presented neoantigen

Induction of antigen-specific T-cell responses through the recognition of the peptide-MHC complex by the T-cell receptor (TCR), leading to the expansion of cytotoxic T lymphocytes (CTLs) that target tumor cells.